Market Access News | pharmaphorum

News

UCB bags FDA approval for second myasthenia gravis drug

Belgian biopharma UCB has been given the green light by the FDA for Zilbrysq as a treatment for generalised myasthenia gravis (gMG), one of two drugs that the company hope

News

Keytruda gets surgery-spanning OK from FDA in early NSCLC

MSD’s Keytruda has become the first immunotherapy in the US that can be used continuously, before and after surgery, in patients with early-stage non-small cell lung cance

News

AZ’s Tagrisso plus chemo get fast FDA review for lung cancer

AstraZeneca will hear back from the FDA in the first quarter of next year about its recent filing of Tagrisso in combination with chemotherapy as a first-line treatment fo

News

MSD gives warning to UK ahead of $1.3bn facility work

In 2017, MSD made the decision to open a $1.32 billion, 220,000 sq ft research facility in the heart of London’s ‘knowledge quarter’ around King’s Cross.

News

Pfizer launches cost-cutting drive as COVID sales fall

Pfizer has said it will shed staff and cut its operating costs by around $3.5 billion, as it faces a shortfall in COVID-19 vaccine and treatment sales, with revenues now e

News

Santhera closes on first approval for DMD drug vamorolone

Swiss biotech Santhera is on the brink of its first regulatory approval for Duchenne muscular dystrophy treatment vamorolone, after getting a positive opinion on the drug

UCB bags FDA approval for second myasthenia gravis drug

Keytruda gets surgery-spanning OK from FDA in early NSCLC

AZ’s Tagrisso plus chemo get fast FDA review for lung cancer

MSD gives warning to UK ahead of $1.3bn facility work

Pfizer launches cost-cutting drive as COVID sales fall

Santhera closes on first approval for DMD drug vamorolone

Bankruptcy threat looms as Quince runs out of options

How to meet your physicians where they are online

News

Editor's Picks